Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03049267 Completed - Clinical trials for Hidradenitis Suppurativa

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis

SMASH
Start date: February 2, 2017
Phase: Phase 2
Study type: Interventional

Study design: A double-blind randomised placebo-controlled trial Intervention: Randomized placebo controlled treatment of 20 HS patients of which fifteen patients will be randomized to apremilast and five patients to placebo. The total duration of the treatment period per subject is 16 weeks. Primary objectives: To evaluate the expression profile of inflammatory cytokines in HS lesional skin at week four (t=4) and week sixteen (t=16): - of patients receiving apremilast compared to placebo; - within both groups relative to baseline (t=0). Secondary objectives: - To prospectively evaluate the clinical efficacy of apremilast. - To assess the effect of apremilast on patient reported outcomes measures. - To assess the short-term safety and tolerability of apremilast in patients with hidradenitis suppurativa.

NCT ID: NCT03001622 Completed - Clinical trials for Hidradenitis Suppurativa

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints (e.g., Hidradenitis Suppurativa Clinical Response (HiSCR), Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) for disease, VAS for pain, Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA), Modified Sartorius Score (mSS)).

NCT ID: NCT02833909 Completed - Clinical trials for Hidradenitis Suppurativa

Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients

Start date: March 2015
Phase: N/A
Study type: Interventional

The objective is to investigate ex vivo the inflammatory response in hidradenitis suppurativa (HS) (activation of an inflammasome, role of pro-inflammatory cytokines) in the skin of patients treated surgically for this disease. The investigators hypothesize that Th17-derived cytokines, especially Interleukin (IL) IL-17, could serve as a relay in the inflammatory process leading to HS severity and recurrences.

NCT ID: NCT02781818 Completed - Clinical trials for Hidradenitis Suppurativa

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

Start date: June 2016
Phase: N/A
Study type: Interventional

Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions. Up to 60 lesions will be treated. Between 20 and 60 patients will be enrolled dependent on the number of lesions they have treated. (up to 3 per patient) Procedures (methods): Injection of triamcinolone or placebo into active lesions of hidradenitis suppurativa

NCT ID: NCT02739828 Completed - Clinical trials for Hidradenitis Suppurativa

Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

HOPE
Start date: April 7, 2016
Phase:
Study type: Observational

The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. The patients will be treated in accordance with normal routine clinical care.

NCT ID: NCT02695212 Completed - Clinical trials for Hidradenitis Suppurativa

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

HS
Start date: July 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).

NCT ID: NCT02643654 Completed - Clinical trials for Hidradenitis Suppurativa

MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB

Start date: December 2015
Phase: Phase 2
Study type: Interventional

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. Although adalimumab is recently licensed for moderate to severe HS, many cases fail to respond or relapse during treatment. Favorable outcomes from a recently conducted double-blind randomized clinical study on the efficacy of anakinra, one interleukin(IL)-1alpha blocker, in hidradenitis suppurativa (HS), led to validate the efficacy of MABp1, a true human antiIL-1α antibody in these cases.

NCT ID: NCT02593604 Completed - Clinical trials for Hidradenitis Suppurativa

Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa

Start date: March 15, 2015
Phase: N/A
Study type: Observational

Patients undergoing wide surgical excision of their hidradenitis suppurativa areas are asked by telephone about their quality of life by standard questionnaires (WHOQOL-BREF, DLQI, Skindex, MHF, FLQA-d) and their sexual function (FSFI, IIEF).

NCT ID: NCT02421172 Completed - Clinical trials for Hidradenitis Suppurativa (Acne Inversa)

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

Start date: April 13, 2015
Phase: Phase 2
Study type: Interventional

This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.

NCT ID: NCT01838499 Completed - Clinical trials for Hidradenitis Suppurativa

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa